Drug intelligence / Profile preview

THP-003

Development stage: Preclinical
Lead developer: THPharm
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

THP-003 is a nanobody drug candidate developed by Jinan Taihe Pharmaceutical Technology. It is in preclinical development for the treatment of hyperlipidemias, targeting diseases within endocrinology and metabolic disease therapeutic areas. The specific molecular target and mechanism of action have not been disclosed publicly as of the latest available information. The drug represents an innovative approach using nanobody technology, which typically involves small antibody fragments designed to bind selectively to disease-related targets[1].

Beyond the preview

Go deeper on THP-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on THP-003.

Explore the full profile